- Home
- XTKG vs LPCN Comparison
XTKG vs LPCN Comparison
Compare XTKG & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XTKG
- LPCN
- Stock Information
- Founded
- XTKG 1997
- LPCN 1997
- Country
- XTKG Singapore
- LPCN United States
- Employees
- XTKG N/A
- LPCN N/A
- Industry
- XTKG
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- XTKG
- LPCN Health Care
- Exchange
- XTKG NYSE
- LPCN Nasdaq
- Market Cap
- XTKG 16.3M
- LPCN 16.1M
- IPO Year
- XTKG 2019
- LPCN N/A
- Fundamental
- Price
- XTKG $1.52
- LPCN $3.29
- Analyst Decision
- XTKG
- LPCN Strong Buy
- Analyst Count
- XTKG 0
- LPCN 2
- Target Price
- XTKG N/A
- LPCN $9.00
- AVG Volume (30 Days)
- XTKG 107.1K
- LPCN 59.4K
- Earning Date
- XTKG 07-07-2025
- LPCN 08-07-2025
- Dividend Yield
- XTKG N/A
- LPCN N/A
- EPS Growth
- XTKG N/A
- LPCN N/A
- EPS
- XTKG N/A
- LPCN N/A
- Revenue
- XTKG $11,611,442.00
- LPCN $3,674,834.00
- Revenue This Year
- XTKG N/A
- LPCN N/A
- Revenue Next Year
- XTKG N/A
- LPCN N/A
- P/E Ratio
- XTKG N/A
- LPCN N/A
- Revenue Growth
- XTKG N/A
- LPCN N/A
- 52 Week Low
- XTKG $0.53
- LPCN $2.68
- 52 Week High
- XTKG $11.60
- LPCN $8.71
- Technical
- Relative Strength Index (RSI)
- XTKG 50.52
- LPCN 51.52
- Support Level
- XTKG $1.25
- LPCN $3.13
- Resistance Level
- XTKG $2.24
- LPCN $3.53
- Average True Range (ATR)
- XTKG 0.25
- LPCN 0.24
- MACD
- XTKG -0.01
- LPCN 0.01
- Stochastic Oscillator
- XTKG 27.27
- LPCN 48.33
About XTKG X3 HOLDINGS CO LTD
X3 Holdings Co Ltd is company which is responsible for globally providing of Technology Solutions and Services across Diverse Industries. It generates revenue from service lines: Application development services; Consulting and technical support services; Subscription services; Trading; and Others, of which maximum revenue is derived from Application development services. Geographically, all of the company's revenue is derived from PRC.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.